Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Pulmonary fibrosis (PF), particularly idiopathic pulmonary fibrosis (IPF), is a progressive interstitial lung disease characterized by excessive deposition of extracellular matrix components, leading to irreversible scarring and decline in lung function. Despite advances in understanding its pathoge...
Saved in:
| Main Author: | Swadip Mishra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | The Journal of Association of Chest Physicians |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jacp.jacp_1_25 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al. -
Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study
by: Camilla S. Graham, et al.
Published: (2025-05-01) -
A clinical case of idiopathic pulmonary fibrosis against the background of comorbid pathology
by: A. V. Teteneva, et al.
Published: (2021-10-01) -
Interstitial lung diseases: a view on the problem
by: O. G. Sych, et al.
Published: (2025-06-01) -
Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)